ImmunityBio(DE:26CA)
€5.46-0.18 (-3.19%)
DE:26CA
ImmunityBio financials statements
€5.46
At close:-0.18 (-3.19%)
ImmunityBio (26CA) Income Statement
19 Followers
ImmunityBio Income Statement
Last quarter (Q3 2026), ImmunityBio's total revenue was $48.84M, an increase of 52.34% from the same quarter last year. In Q3, ImmunityBio's net income was $-184.55M. See ImmunityBio’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 113.29M | $ 14.74M | $ 622.00K | $ 240.00K | $ 934.00K | |
| $ 112.53M | $ 14.74M | $ 622.00K | $ 240.00K | $ 934.00K | |
| $ 368.56M | $ 358.93M | $ 362.87M | $ 351.54M | $ 331.21M | |
| Depreciation and Amortization | $ 15.53M | $ 17.55M | $ 18.51M | $ 18.26M | $ 14.24M |
| $ -223.56M | $ -264.43M | $ -478.66M | $ -351.88M | $ -320.75M | |
| $ -256.03M | $ -344.18M | $ -362.25M | $ -351.30M | $ -330.28M | |
| $ -95.58M | $ -69.46M | $ -221.64M | $ -65.99M | $ -19.56M | |
| $ -351.61M | $ -413.64M | $ -583.89M | $ -417.29M | $ -349.84M | |
| $ -351.40M | $ -413.56M | $ -583.20M | $ -416.57M | $ -346.79M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.38 | $ -0.59 | $ -1.15 | $ -1.04 | $ -0.89 |
| Diluted EPS | $ -0.38 | $ -0.62 | $ -1.15 | $ -1.04 | $ -0.89 |
| Weighted Average Shares Outstanding | 919.86M | 697.31M | 508.64M | 399.90M | 389.23M |
| Weighted Average Shares Outstanding (Diluted) | 919.86M | 700.44M | 508.64M | 399.90M | 389.23M |
Currency in USD
